
## PRECISION PANC UPDATE

The first half of 2019 have continued to be very busy for the PRECISION-Panc project.

Since January 11 new sites have opened to the Master Protocol and 6 have opened since the last update email — Churchill Hospital, Castle Hill Hospital, Poole Hospital, the Freeman, Newcastle, Royal Bournemouth Hospital and the Royal Albert Edward Infirmary — we welcome all the new sites on board!

We have recruited a total of 220 patients into the Master Protocol, 131 since the start of the year.

171 of them have gone on to be registered, 110 since the beginning of the year



## PRECISION PANC CURRENT NUMBERS

Site	PI	Date Opened	Patients Entered	Patients Registered
Glasgow Royal Infirmary	Colin McKay	28Nov2017	75	55
Aberdeen Royal Infirmary	Bassam Alkari	22Feb2018	20	11
Royal Marsden	Naureen Starling	27Mar2018	10	6
UCLH	Daniel Hochhauser	16Apr2018	12	11
Addenbrookes	Bristi Basu	25Apr2018	24	22
The Christie	Juan Valle	27Apr2018	18	17
Weston Park	Jonathan Wadsley	09Jul2018	7	7
Bristol Oncology Centre	Stephen Falk	13Aug2018	15	14
Imperial	Harpreet Wasan	22Aug2018	2	2
Nottingham	Arvind Arora	19Oct2018	5	5
Royal Free	Giuseppe Fusai	19Nov2018	2	2
Manchester Royal	Derek O'Reilly	06Dec2018	3	1
Ninewells Hospital, Dundee	Asa Dahle-Smith	21Dec2018	2	2
St George's	Anna-Mary Young	04Jan2019	7	6
Southampton	Andrew Bateman	17Jan2019	4	2
St James's	Andrew Smith	22Jan2019	1	0
Queen Elizabeth, Birmingham	Yuk Ting Ma	12Mar2019	0	0
King's College	Andreas Prachalias	29Mar2019	1	0
Churchill Hospital	Kinnari Patel	02Apr2019	3	2
Castle Hill Hospital	Anthony Maraveyas	05Jun2019	1	1
Poole	Lachlan Ayres	12Jun2019	1	0
Freeman	Kofi Oppong	18Jul2019	5	4
Royal Bournemouth	Tamas Hickish	25Jul2019	1	1
RAEI, Wigan	Richard Keld	20Aug2019	1	0

## PRECISION PANC UPDATE

### Sites in set up

Cumberland Infirmary
Milton Keynes
Morriston
Mount Vernon
Northern Ireland Cancer Center
Raigmore Hospital
Royal Liverpool
Western General, Edinburgh

### Sequencing

We have analysed data from 96 tumour/normal pairs to date. We plan to start getting the genomic reports back to site by the end of this month. Please remember that these reports will be for research only and all mutations should be confirmed by a NHS lab prior to making any change to the patient's management.




## PRIMUS 001 SUMMER UPDATE

The first six months of 2019 have also been very busy and successful for PRIMUS 001.

Since January 10 new site have opened to PRIMUS 001, 8 since the last update— Ninewells, Churchill, Imperial, QE Birmingham, Royal Free, Freeman, Royal Bournemouth, Castle Hill

52 patients have been randomised to PRIMUS 001 since January bringing the Recruit all-total number of patients to 77




## PRIMUS 002 SUMMER UPDATE

#### PRIMUS-002

5 patients to date. At present only Glasgow is open to recruitment but an amendment that has been submitted to the regulatory authorities should allow the 10 sites in set up to open as soon as approvals are in place.

An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal AdenoCarcinoma (PDAC), focusing on biomarker and liquid biopsy development



## STUDIES IN SET UP

PRIMUS 004 – This second line, metastatic, umbrella study has recently been endorsed by CRUK. The protocol is in development and the study should open its first appendix (AZD6738 and olaparib) Q1 2020

PRIMUS 005 (STAR-PAC2) - A phased IIb randomised study repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer. This study is in set up and should open Q1-2 2020

#### Other Potential Studies / Collaborations

A trial looking at Olaparib & pembrolizumab being developed by Pippa Corrie and the Cambridge team.

A trial targeting KRAS wild type looking at Erlotinib and Gemcitabine in the metastatic setting is in development

We also hope to work with other studies including MENAC and Be-Alpha to help build the Precision-Panc platform and have more options for patients with pancreatic cancer

f you have a study idea that you would like to bring into the PRECISION-Panc Platform the next joint NCRI sub-group and Therapeutic Testing Board meeting will take place on 21<sup>st</sup> October in Glasgow. Please contact <a href="mailto:Judith.Dixon@glasgow.ac.uk">Judith.Dixon@glasgow.ac.uk</a> if you have an idea you would like to bring to this group

#### Contact details

Site set up/PRIMUS 001, 002, 004 – Sarah Bradley (<u>sarah.Bradley@Glasgow.ac.uk</u>)
Precision-Panc Platform/Translational issues – Judith Dixon-Hughes
(<u>Judith.Dixon@Glasgow.ac.uk</u>)

Follow us on twitter <a href="https://twitter.com/precisionpanc">https://twitter.com/precisionpanc</a>
Review the website <a href="https://www.precisionpanc.org/">https://twitter.com/precisionpanc</a>



# PRECISION PANC SPRING 2019 COMPLETED STUDIES

PRIMUS 003 (EVEREST) – A phase Ib and II open label, multi centre study of MEDI4736 evaluated in different combination in patients with metastatic ductal adenocarcinoma.

This trial completed recruitment and the database is now locked. The study samples have been transferred to GPOL for sequencing. DNA/RNA extraction is now complete and sequencing will start very soon



# PRECISION PANC SPRING 2019 PATIENT & PUBLIC ENGAGEMENT

Did you know that Precision-Panc has it's own Patient Public Advisory Group?

This group was set up by CRUK and PCUK and allows any Precision-Panc researcher to go to the group with study ideas, to review patient facing material or any other topic where patient input would be useful. We are so lucky to have this wonderful resource and it has already proved to be extremely useful. Please get in touch if you would like the PPAG to review any material or study idea.

At the start of September a roundtable meeting was set up in Manchester so Precision-Panc researchers could meet with representatives from the four main pancreatic charities (Pancreatic Cancer UK, Pancreatic Cancer Scotland, Pancreatic Cancer Action and the Pancreatic Cancer Research Fund) to look at ways of how recruitment to clinical trials in general, and Precision-Panc specifically, could be increased. This was an fantastic day and is currently being transcribed. Once actions have been put in place these will be shared with all sites.

